Mitsubishi Tanabe To Settle Japanese Hepatitis Suit
This article was originally published in PharmAsia News
Executive Summary
Japan's Mitsubishi Tanabe Pharma and its subsidiary expect to reach another settlement in the long-running case of patients infected with hepatitis C by tainted drug products. One of the lawyers involved in suits against the company says they expect to settle as early as late August. Plaintiffs and their lawyers have been meeting with company representatives to resolve the suit. One of the lawyers said the Mitsubishi Tanabe board expects to deliberate a draft of an agreement similar to the one plaintiffs presented June 23 that requires an apology from executives of the parent plant and its Benesis subsidiary. Nihon Pharmaceutical also is named in the suit. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.